Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
Items 401–500 of 647
Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies
Farré‐Colomés, À., Rublinetska, O., & Soto-Angona, Ó. (2026) · Discover Mental Health · doi:10.1007/s44192-026-00384-w · Cited by 3
“…reviews, including systematic reviews, have examined psychedelic-assisted psychotherapy treatment, they predominantly focus on clinical outcomes and therapeutic effects in psychiatric disorders, typically assessed via self-reported and clinician-administered symptom rating scales [4, 19, 20].”
Not a Standalone Treatment: Considerations for Psychedelic‐Assisted Therapy
Murphy, S., Stewart, E., Winship, J. R., Kampel, L., Stiel, B., & Ellis, J. (2026) · Brain and Behavior · doi:10.1002/brb3.71280 · Cited by 2
“Psychedelic-assisted therapy (PAT) has recently emerged as a promising intervention for these patients (Kalfas et al. 2023 ; Ko et al. 2023 ; Krediet et al. 2020 ; Reiff et al. 2020 ; Yao et al. 2024 ).”
Schüle, C., Sobieraj, A., & Rogg, H. V. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2742-4611 · Cited by 3
“Synthetische Psychede - lika wie z. B. DMT, Psilocybin, Lysergsäure-Diethylamid (LSD) oder 5-Methoxy-N,N-Dimethyltryptamin (5-MeO-DMT; Mebufotenin) sind Substanzen, die tiefgreifende Veränderungen der Wahrnehmung, des emotionalen Er-lebens und des Bewusstseins hervorrufen können [14].”
Psychedelic-induced hypomania and mania: a systematic review and meta-analysis
Eskinazi, M., Nasserdine, R., Cusin, R. M., Baniotoupoulos, P., Saccaro, L. F., Pieri, M. D., Corino, T., Seragnoli, F., Briefer, J.-F., Brakha, T. A., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03657-6 · Cited by 3
“Clinical guidance remains limited [12, 13], and decision-making around the inclusion of bipolar patients in therapeutic protocols is often based on expert opinion or indirect evidence [14].”
Steinberg, M. I., Rosenberg, P., & Garcia‐Romeu, A. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00395-3 · Cited by 3
Self-perception and self-recognition while looking in the mirror on psilocybin
Elias, S., Spivak, S., Alverez, A., Olivares, A. G., Ferrol, M., & Keenan, J. P. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00251 · Cited by 3
Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy
Shah, F. I., Shehzadi, S., Akram, F., Haq, I. U., Javed, B., Sabir, S., Kazim, Y., & Ashfaq, S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00994-7 · Cited by 4
“Notably, studies like the Concord Prison Experiment showed positive outcomes in the application of psilocybin in the discipline of therapeutic psychology [35].”
Rodrigues‐Ribeiro, L., Resende, B. L., Dias, M. L. P., Lopes, M. R., de Barros, L. L. M., Moraes, M. A., Verano‐Braga, T., & Souza, B. R. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-50624-6_6 · Cited by 4
Chen, Y., Wang, T., Tan, Y., & Li, D. (2024) · Digital Health · doi:10.1177/20552076241249869 · Cited by 3
“18,19 This enables the utilization of psychedelic substances in conjunction with psychological interventions.”
BackgroundTran, J., Elkins, A. C., Vassiliadis, S., Cogan, N. O. I., & Rochfort, S. J. (2024) · Psychoactives · doi:10.3390/psychoactives3040032 · Cited by 2
Ryan, W. C., & Heifets, B. D. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2421895 · Cited by 7
“Careful control of context, or “set and setting” (Carhart-Harris et al. 2018), furthers clinical benefit (Reiff et al. 2020).”
Neurochemical characterization of 5-HT 2A R partial agonists with simultaneous PET-MRI
Bagdasarian, F. A., Larsen, K., Hong, D., Fisher, P. M., Mandeville, J. B., Sander, C. Y. M., Wey, H., & Hansen, H. D. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241302937 · Cited by 4
Exploring the Role of Psychedelic Experiences on Wellbeing and Symptoms of Disordered Eating
Loh, N., & Luke, D. P. (2025) · Psychoactives · doi:10.3390/psychoactives4010007 · Cited by 2
Psychedelic Use and Behavioral Addictions
Brasher, T. J., Rosen, D., & Spinella, M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2474244 · Cited by 2
“…indicate their effectiveness in the treatment of depression (Fang, Yang, and Zhang 2024), anxiety (Leger and Unterwald 2022), PTSD (Luoma et al. 2020; Reiff et al. 2020; Varker et al. 2021), and substance use disorder (SUD; Andersen et al. 2021; DiVito and Leger 2020; Mertens and Preller 2021).”
Is there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 4
Flynn, L., Rondeau, M., Kršák, M., & Shannon, S. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0050 · Cited by 4
Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons
Yang, L., Li, H., & Wang, X. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01415-2 · Cited by 3
“With its unique ability to modulate serotonin and glutamate systems, psilocybin offers a groundbreaking therapeutic approach for several treatment-resistant conditions, including depression, substance use disorders, PTSD, chronic pain, and OCD [15, 16].”
Knowledge and attitudes about the use of psychedelic drugs among psychiatric professionals in Korea
Choi, W.-S., Hong, J., Jang, S.-H., Lee, J. G., Sohn, I., Lilienthal, F., Seo, J. S., Kim, N.-Y., Jang, O.-J., & Jon, D. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00424 · Cited by 3
Pasifika healthcare professionals' perspectives on psychedelic-assisted therapy
Nuha, M., Reynolds, L., & Fia’Ali’i, J. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00413 · Cited by 2
The Ethics of Set and Setting in Psychedelic Psychotherapy
Patch, K., & Smith, W. (2025) · Neuroethics · doi:10.1007/s12152-025-09600-w · Cited by 2
Psychedelics - A Cure for Sexual Trauma or a Risk Factor in Recreational and Treatment Settings?
Struble, C. A. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00372-x · Cited by 2
Qualitative analysis of first-person accounts of noetic experiences
Wahbeh, H., Fry, N., Speirn, P., Hrnjic, L., Ancel, E., & Niebauer, E. (2021) · F1000Research · doi:10.12688/f1000research.52957.1 · Cited by 6
The cranial windows of perception
DiBerto, J. F., & Roth, B. L. (2021) · Neuron · doi:10.1016/j.neuron.2021.07.017 · Cited by 2
“…neurons in driving epilep- Neuron 109 Reiff, C.M., Richman, E.E., Nemeroff, C.B., Carpenter, L.L., Widge, A.S., Rodriguez, C.I., Kalin, N.H., and McDonald, W.M.; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research (2020).”
BackgroundHallucinogen-Related Disorders
Kim, K. K., & Roberts, D. E. (2021) · Psychiatry update · doi:10.1007/978-3-030-86430-9_5 · Cited by 4
da Silva, J. R. M. Q., & Mendonça, M. A. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i8.11098 · Cited by 2
A Heuristic Approach: Against Consensus Definitions of Psychedelics
Lepow, L., Kronman, H. G., & Yehuda, R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0031 · Cited by 2
Husain, M. I., Umer, M., & Mulsant, B. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2063274 · Cited by 2
Commentary: Psychedelic Psychiatry's Brave New World
Nobile, B., Olié, É., & Courtet, P. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.594077 · Cited by 2
“A common mechanism of action through modulation of glutamatergic transmission (leading to neuroplastic adaptations) could underlie the antisuicidal action of psilocybin and ketamine (2).”
BackgroundInfluentialWießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · doi:10.54985/peeref.2209p9281218 · Cited by 2
Wießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · doi:10.54985/peeref.2210p1472035 · Cited by 2
Chapter 35. Combining Medications and Psychotherapy
Mintz, D. L. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg35 · Cited by 5
Rudnick, A., Shaheen, A., Lefurgey, S., & Nolan, D. (2023) · Encyclopedia · doi:10.3390/encyclopedia3040095 · Cited by 3
Meshkat, S., Fang, H., Sousa-Ho, R., Zeifman, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0039 · Cited by 3
Enghoff, O., Petersen, M. A., Holm, S., & Hesse, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00415 · Cited by 1
Leveraging psychedelic neuroscience to boost human creativity using artificial intelligence
Ross, B. M. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1589086 · Cited by 1
“Other compounds with psychedelic-like properties include MDMA, which enhances mood and empathy via serotonin, dopamine, and norepinephrine, and that of ketamine, an anesthetic with rapid antidepressant effects thought to act through glutamatergic modulation (Bowdle et al., 1998; De la Torre et al., 2000).”
InfluentialPsilocybin as a psychophysical adaptogen in chronic pain rehabilitation
Cherup, N. P., & Finan, P. H. (2025) · Journal of Pain · doi:10.1016/j.jpain.2025.105507 · Cited by 2
Suay, D., Aicher, H., Singer, B., Mueller, M. J., Jelusic, A., Calzaferri, L., Springfeld, P., Dornbierer, D., & Scheidegger, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251353256 · Cited by 1
“Psychedelic drugs have shown promising outcomes as potential treatments for mental disorders (Carhart-Harris and Goodwin, 2017; Nichols and Walter, 2021; Reiff et al., 2020).”
Jevtić, M. (2025) · Engrami · doi:10.5937/engrami47-57385 · Cited by 1
Kheirkhah, M., Mcdonald, N., Aepfelbacher, J., Rengasamy, M. L., Shivanekar, S. P., Spotts, C., Cooper, I., Baumeister, A., Bell, E., Do-Nguyen, K., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1642025 · Cited by 5
A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder
Srivastava, A. B., & Gold, M. S. (2025) · Brain Sciences · doi:10.3390/brainsci15111190 · Cited by 3
Lindegaard, T., & Käll, A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120732 · Cited by 1
Afsharnia, S., Liang, V., Lunsky, Y., Orsini, A., Tint, A., & Lin, H. (2025) · PLOS mental health. · doi:10.1371/journal.pmen.0000514 · Cited by 1
“[28–30].”
Vijay, G. K., Joga, R., Yerram, S., Waiker, S., Gandhi, K., Sowndharya, M., & Srivastava, S. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10393-5 · Cited by 1
Camargos, G. S., de Faria, G. M., Lourenço, M., & Filho, G. M. D. A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1726909 · Cited by 4
Toward Greater Diversity in Psychedelic Science
Hughes, M. (2026) · Psychiatric Services · doi:10.1176/appi.ps.20250169 · Cited by 3
He, Z., Wang, Y., Chen, J., Cheng, J., Feng, Y., Niu, S., & Yan, J. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02165-y · Cited by 1
“The results indicate its potential effectiveness in improving depressive treatments for depression [ 42, 43].”
Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"
Jerotić, S., Čolović, O., & Marić, N. P. (2026) · Medicinska istrazivanja · doi:10.5937/medi0-62051 · Cited by 2
Negrine, J. J., Bright, S. J., Barratt, M. J., Pennell, M., Barnett, A., Bennett–Levy, J., & Piatkowski, T. M. (2026) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2026.2645025 · Cited by 1
Mei, X., Wu, H., Yuan, T., Samsom, J., Ying, S., Liu, X., Xu, T., Liu, F., & Shen, Y. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03538-y · Cited by 2
“These are of particular concern when anesthetics are used off-label [100, 101].”
Should People With a History of Psychosis Be Included in Psychedelic Research?
Rajwani, K. (2026) · Canadian Journal of Bioethics · doi:10.7202/1124213ar · Cited by 1
Classic psychedelics in obsessive–compulsive disorder: a circuit-based framework
Ali, S. S., Carhart-Harris, R. L., & Sieg, K. G. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00626-4 · Cited by 1
Castellano-Ramírez, D., Hernández‐Álvarez, E., Borkel, L. F., Rojas‐Hernández, J., Hernández, D. J. Q., & Henríquez‐Hernández, L. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344698 · Cited by 1
“Such a balanced perspective is consistent with the broader scientific literature, which highlights both the potential benefits of psychedelics and the need for careful screening, supervision, and regulatory oversight [31,36].”
Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations
Marazziti, D., Gambini, M., Gurrieri, R., Russomanno, G., Sità, G., Pescini, E., DIGIUSEPPE, F. R., & Mucci, F. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2654682 · Cited by 2
“…the FDA has granted Breakthrough Therapy designation to MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) and to psilocybin-assisted therapy for treatment-resistant and major depressive disorders, thereby accelerating development but not prejudging eventual approval [36,38].”
Psychedelic Art Therapy: The Intersection of Psychedelics, Creativity, and Art Therapy
Wilkinson, R. A., & Gursky, A. B. (2026) · Art Therapy · doi:10.1080/07421656.2026.2641876 · Cited by 1
“A challenge in standardizing psychedelic therapy protocols is the variation in drug characteristics, including dosing frequency and duration of the psychedelic experience (Reiff et al., 2020).”
Robinson, J., Wallace, N., Cassidy, E. K., Lake, S., & Lucas, P. (2026) · Contemporary Drug Problems · doi:10.1177/00914509261444382 · Cited by 1
“This fi nding underscores the potential of psychedelics to offer a complementary approach for addressing complex and treatment-resistant mental and physical health conditions, many of which remain inadequately managed by current methods (Reiff et al., 2020).”
Hadash, Y., Dar, O., Oren-Schwartz, R., & Bernstein, A. (2026) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2026.2656720 · Cited by 4
Low, F., & Earleywine, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2673844 · Cited by 3
Bhat, A., Zolali, E., Sakib, M. A., Rahimian, M., McMahon, L. R., German, N., & Obeng, S. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00202 · Cited by 2
Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review
da Cruz, L. V. M., Beserra, F. R., FREIND, J. M. K., Rodrigues, S. E., & Mograbi, D. C. (2026) · Journal of Clinical Psychology · doi:10.1002/jclp.70167 · Cited by 3
“The therapeutic potential of psychedelic substances has garnered increasing scientific interest in recent years, leading to a surge in rigorous research efforts (see Yao et al. 2024; Reiff et al. 2020).”
Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test
Seillier, L., Seillier, A., Zvolska, M. A., & Šlamberová, R. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261458349 · Cited by 1
Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1
Werle, I., Probst, M. E. C., & Bertoglio, L. J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261464979 · Cited by 2
Experience, plasticity, and context: Beyond single-level models of antidepressant action
Eckert, D. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473402 · Cited by 1
Complex Fatal Self-Harm Under Psilocybin Intoxication: Suicidal Manner of Death or Not?
Labonté, C., & Walker, A. E. (2026) · Academic Forensic Pathology · doi:10.1177/19253621261468084 · Cited by 1
The rebirth of psychedelic psychiatry
Holoyda, B. J. (2021) · Current Psychiatry · doi:10.12788/cp.0079 · Cited by 1
Calati, R. (2021) · Neuropsychobiology · doi:10.1159/000515932 · Cited by 1
Hammel, R. L., Gulliver, B. J., Sukich, S. N., & Abraham, S. (2022) · International Journal of Science and Research Methodology · doi:10.25166/ijsrm/2022.20.3.2 · Cited by 2
Regen, F., & Benkert, O. (2020) · Springer eBooks · doi:10.1007/978-3-662-61753-3_1 · Cited by 2
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2046-5202 · Cited by 1
“Die Behandlung mit Psilocybin ist keine rein psychopharmakologische Behandlung, sondern wird psychothera-peutisch unterstützt, oftmals mit der sogenannten Psilocybin-ge-stützte Psychotherapie (psilocybin-assisted psychotherapy; PAP) [95].”
THE SEROTONIN 5-HT 2A RECEPTOR AS AN EVOLVING NEUROTHERAPEUTIC TARGET
Bolinger, A. A., Anastasio, N. C., Cunningham, K. A., & Zhou, J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch03 · Cited by 1
The Age of Aquarius revisited: implications of a new psychedelic era
Price, L. H. (2023) · The Brown University Psychopharmacology Update · doi:10.1002/pu.31110 · Cited by 1
“I say “so-called” because the nomenclature around these drugs is not universally agreed upon, but I think a consensus is building around something like the categorization proposed by Reiff et al. (2020).”
BackgroundPharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Ghosh, P., & Sur, D. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822258502231120074036 · Cited by 1
Khanna, R. (2024) · Journal of Indira Gandhi Institute Of Medical Sciences · doi:10.4103/jigims.jigims_60_23 · Cited by 1
3, 4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy: what the pharmacist needs to know
Gallo, A. T., & Fitzgerald, P. B. (2024) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1921 · Cited by 1
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Ashraf, N. (2024) · Journal of Pakistan Psychiatric Society · doi:10.63050/jpps.21.02.935 · Cited by 1
The role of psilocybin in depressive disorders
Najib, J. S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2396536 · Cited by 1
Current practice in pharmacological treatment of generalized anxiety disorder
Useinova, A. N., Ayrapetova, A. A., Savshak, M. V., Li, Y. R., Tarusov, N. I., Kondakov, D. M., Boyko, M. V., Solomko, D. V., Seitmemetova, U. M., & Davydova, D. S. (2024) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2407-10 · Cited by 1
Blay, M., Benmakhlouf, I., & Speranza, M. (2025) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2025.100245 · Cited by 1
Bires, J. L. (2025) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2025.2482917 · Cited by 1
Vinarcsik, L., Smoller, C., & Grossberg, G. T. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01221-5 · Cited by 1
ZULLINO, D. F., & Szczesniak, L. (2021) · Swiss Archives of Neurology Psychiatry and Psychotherapy · doi:10.4414/sanp.2021.03219 · Cited by 1
Kang, M., Mackay, L., Christie, D., Callon, C., & Argento, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00190 · Cited by 1
Ferreira, J. P. E., Bortoli, S., & Pereira, A. V. (2022) · Revista Virtual de Química · doi:10.21577/1984-6835.20220053 · Cited by 1
“Recentemente, as indolaminas psicodélicas (psilocibina e DMT) e alguns entactógenos (MDMA e naftilisopropilamina) têm sido apontados como agentes terapêuticos em potencial de distúrbios depressivos.(2) Apesar de apresentarem analogias estruturais, são duas classes distintas, principalmente quanto aos prováveis mecanis…”
BackgroundInfluentialThe future of hallucination research: Can hallucinogens and psychedelic drugs teach us anything?
Waters, F. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114968 · Cited by 3
Psilocybin Therapy for Major Depressive Disorder: A Systematic Review
Venugopal, K. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.489 · Cited by 3
“Following dosing sessions, integration sessions are held with the same therapists to discuss the patients' experiences and any potentially meaningful insights or details of emotional challenges overcome [19, 24-25].”
BackgroundInfluentialAre Psychedelics Something New in Teaching Psychopharmacology?
Louie, A. K., Beresin, E. V., Coverdale, J., Balon, R., Guerrero, A. P. S., Morreale, M. K., Aggarwal, R., & Brenner, A. M. (2020) · Academic Psychiatry · doi:10.1007/s40596-020-01294-x · Cited by 2
Bell, A. K., Watt, B. R., Flores, A. L., Rodriguez, S. R., Smith, D. T., & Stauffer, C. S. (2025) · Research Square · doi:10.21203/rs.3.rs-5908748/v1 · Cited by 2
Public opinion and the morality of drug use : experimental and time-series analyses
Kuettel, B. T. (2023) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/k6jy-e0ga · Cited by 3
Rossi, G. N. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-08022021-150020
Depression(stherapie) – ein Feld der Integration?
Schauenburg, H. (2021) · PiD - Psychotherapie im Dialog · doi:10.1055/a-1215-1541
Kloft, L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210623lk
Stein, D. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00209-0
Stage Six: Accessing Passion and Other Inner Resources
Broder, M. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-00661-6_8
PSILOCIBINO TERAPIJOS VEIKSMINGUMAS, GYDANT SUNKIĄ DEPRESIJĄ
Stumbraitė, A. (2022) · Health Sciences · doi:10.35988/sm-hs.2022.189
Psychopharmacology and social psychiatry
Werneke, U. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780198861478.003.0059
Silveira, G. D. O. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2020.tde-25082022-101857
Klassieke psychedelica als behandeling voor depressie: waar staan we vandaag?
Slechten, F., & Hert, M. D. H. M. D. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.075
РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ
Matrenitsky, V. L. (2022) · Likarska sprava · doi:10.31640/2706-8803-2022-(3-4)-04 · Cited by 3
Tarrant, J. (2022) · Biofeedback · doi:10.5298/1081-5937-50.03.03 · Cited by 1
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.